Category

News
Vall d’Hebron Institute of Research (VHIR) and the Liver Unit of Vall d’Hebron University Hospital hosted a scientific meeting in Barcelona last May 11th & 12th to discuss the next steps in the development of platform trials for Non-Alcoholic Steatohepatitis (NASH) disease. The meeting brought together academic and industry experts closely collaborating in EU-PEARL to...
Read More
By Sarai Rodríguez Navarro and Joan Genescà (VHIR) EU-PEARL (European Union-Patient-cEntric clinicAl tRial pLatforms), an IMI (Innovative Medicines Initiative)-founded project,  was conceived as a means to change the paradigm of clinical trials in Europe, by promoting more adaptive, efficient and patient-centered clinical trials, thus contributing to accelerate drug development and the access to new and...
Read More
EU-PEARL is developing methodologies and tools to enable the scale-up of platform trials across Europe, and potentially worldwide. These include innovative Information and Communication Technology (ICT) methods and platform specifications to support platform trial queries using federated hospital real-world data. In this article, the authors describe the tools being developed and how these will pave...
Read More
Luca Sforzini is M.D., Psychiatrist, Ph.D. student at Stress, Psychiatry & Immunology (SPI) Lab, Institute of Psychiatry, Psychology and Neuroscience, King’s College London (UK). As an early career investigator, he shares in this interview his views on mental health research and  his experience at EU-PEARL.     What started your scientific vocation? I have always been...
Read More
  By members of EU-PEARL Patient Advisory Group (PAG) Claas Röhl,  Livia Alimena and Fiona Greenhalgh, and Juan Espinosa, member of the Expert Advisory Group (EAG). Patient and community engagement in R&D is essential to understand the needs of patients and tailor clinical trials accordingly. While patient engagement is on the rise, we still see...
Read More
  When and what started your scientific vocation? I have always been a curious person and have been fascinated by science. But it was when I started my master’s degree in statistics that I became interested in research, particularly in statistics applied to medicine. This combines actual challenges in health with the need to adapt...
Read More
By Vlad Ratziu (Institute for Cardiometabolsim and Nutrition, Assistance Publique Hôpitaux de Paris, Sorbonne Université, France) and Nicholas Di Prospero (Janssen Pharmaceutical Research and Development, NJ USA). Nonalcoholic fatty liver disease is the most common chronic liver disease and steatohepatitis (a.k.a. nonalcoholic or metabolic steatohepatitis, NASH), its progressive form, is responsible for a growing number...
Read More
The EU-PEARL project is pleased to invite you to a webinar on non-concurrent controls in platform trials on the 24 of February 2022. At the webinar we will discuss with external stakeholders when and how to utilise non-concurrent control data in platform trials.  The speakers/panelists include statisticians from regulatory agencies, industry and academia. Webinar on...
Read More
Meyer received the award for his paper “Decision rules for identifying combination therapies in open-entry, randomized controlled platform trials”. The prestigious Arthur-Linder-Prize is awarded every two years by the Austrian-Swiss Region of the International Biometric Society (IBS-ROeS) to support young scientists in honor of Prof. Arthur Linder for a research paper in the field of...
Read More
What started your scientific vocation? Ever since I was little, I have been drawn to scientific subjects. Even though I really had no idea of what science was, I chose to study biology at University mostly because it was something I was keen on learning. It was during my University studies that I first discovered...
Read More
1 2 3 4 5

Sign up to stay informed


    We will process your data to deliver our quarterly updates to your inbox. You can view our Privacy Policy here or contact us at info@eu-pearl.eu